These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 22265063

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J, Hernandez Aguado JJ, San Martín M, Ramirez Boix P, Cedillo Gómez S, López N.
    Hum Vaccin Immunother; 2019 Jan; 15(7-8):1949-1961. PubMed ID: 30698488
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
    Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T.
    BMC Infect Dis; 2017 Jul 18; 17(1):502. PubMed ID: 28720082
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Health and economic implications of HPV vaccination in the United States.
    Kim JJ, Goldie SJ.
    N Engl J Med; 2008 Aug 21; 359(8):821-32. PubMed ID: 18716299
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Aug 21; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.
    Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N.
    Int J Gynecol Cancer; 2010 Apr 21; 20(3):385-92. PubMed ID: 20375802
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
    Michaeli DT, Stoycheva S, Marcus SM, Zhang W, Michaeli JC, Michaeli T.
    Clin Drug Investig; 2022 Apr 21; 42(4):333-343. PubMed ID: 35294726
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.